Literature DB >> 27668650

Adropin - physiological and pathophysiological role.

Natalia Marczuk1, Elżbieta Cecerska-Heryć1, Anna Jesionowska2, Barbara Dołęgowska1.   

Abstract

Adropin is a peptide hormone that was discovered in 2008 by Kumar et al. This protein consists of 76 amino acids, and it was originally described as a secreted peptide, with residues 1-33 encoding a secretory signal peptide sequence. The amino acid sequence of this protein in humans, mice and rats is identical. While our knowledge of the exact physiological roles of this poorly understood peptide continues to evolve, recent data suggest a role in energy homeostasis and the control of glucose and fatty acid metabolism. This protein is encoded by the Enho gene, which is expressed primarily in the liver and the central nervous system. The regulation of adropin secretion is controversial. Adropin immunoreactivity has been reported by several laboratories in the circulation of humans, non-human primates and rodents. However, more recently it has been suggested that adropin is a membrane-bound protein that modulates cell-cell communication. Moreover, adropin has been detected in various tissues and body fluids, such as brain, cerebellum, liver, kidney, heart, pancreas, small intestine, endothelial cells, colostrum, cheese whey and milk. The protein level, as shown by previous research, changes in various physiological and pathophysiological conditions. Adropin is involved in carbohydrate-lipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. The knowledge of this interesting protein, its exact role and mechanism of action is insufficient. This article provides an overview of the existing literature about the role of adropin, both in physiological and pathophysiological conditions.

Entities:  

Year:  2016        PMID: 27668650     DOI: 10.5604/17322693.1220082

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  4 in total

1.  Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line.

Authors:  Ewelina Stelcer; Paulina Milecka; Hanna Komarowska; Karol Jopek; Marianna Tyczewska; Marta Szyszka; Marta Lesniczak; Wiktoria Suchorska; Karlygash Bekova; Beata Szczepaniak; Marek Ruchala; Marek Karczewski; Tomasz Wierzbicki; Witold Szaflarski; Ludwik K Malendowicz; Marcin Rucinski
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

2.  Serum Adropin Levels in Patients on Hemodialysis.

Authors:  Dijana Boric-Skaro; Maja Mizdrak; Mirko Luketin; Dinko Martinovic; Daria Tokic; Marino Vilovic; Daniela Supe-Domic; Tina Ticinovic Kurir; Josko Bozic
Journal:  Life (Basel)       Date:  2021-04-11

3.  The effectiveness of serum S100B, TRAIL, and adropin levels in predicting clinical outcome, final infarct core, and stroke subtypes of acute ischemic stroke patients.

Authors:  Ozge Altintas Kadirhan; Okkes Taha Kucukdagli; Bedia Gulen
Journal:  Biomedica       Date:  2022-05-01       Impact factor: 1.173

4.  Elastic band resistance training increases adropin and ameliorates some cardiometabolic risk factors in elderly women: A quasi-experimental study.

Authors:  Akbar Azamian Jazi; Esmaeil Moradi Sarteshnizi; Mahshid Fathi; Zahra Azamian Jazi
Journal:  BMC Sports Sci Med Rehabil       Date:  2022-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.